Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968212 · ClinicalTrials.gov registry record · Phase 2
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
A Phase 2 study of Mycobacterium Avium Complex, sponsored by Oregon Health and Science University.
- Active
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 7
- Study locations
NCT02968212: Active Phase 2 study of Mycobacterium Avium Complex, sponsored by Oregon Health and Science University.
NCT02968212 is a Phase 2 study of Mycobacterium Avium Complex that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 102 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968212, a Phase 2 study of Mycobacterium Avium Complex, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD
Primary Outcome
sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.
Conditions Studied
Interventions
- DRUG Clofazimine
- OTHER sugar pill
Study Locations (7)
Colorado
- National Jewish Health - Denver
Florida
- University of South Florida - Tampa
Illinois
- University of Chicago - Chicago
Louisiana
- Louisiana State University - Baton Rouge
Maryland
- National Heart, Lung and Blood Institute - Bethesda
Oregon
- Oregon Health & Science University - Portland
Texas
- University of Texas Health Science Center - Tyler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT02968212 still lists
NCT02968212 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Mycobacterium Avium Complex appearing as the primary indexed condition, and to 2 interventions - of which Clofazimine is the first listed.
NCT02968212 lists 7 locations in 7 states (Colorado, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT02968212 about?
NCT02968212 is a clinical study titled "Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)". The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD
What is the current status of trial NCT02968212?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2017-04-11. Estimated completion is 2026-03.
What conditions does trial NCT02968212 study?
This clinical trial studies the following conditions: Mycobacterium Avium Complex.
What interventions are being tested in trial NCT02968212?
The interventions under investigation include: Clofazimine (DRUG), sugar pill (OTHER).
Who is sponsoring clinical trial NCT02968212?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968212 being conducted?
This trial has 7 study locations across Colorado, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycobacterium Avium Complex
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02968212's enrollment target sits among peer trials
102 668th of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI